Omsland, Tone Kristin
Solberg, Lene B.
Bjørnerem, Åshild
Borgen, Tove T.
Andreasen, Camilla
Wisløff, Torbjørn
Hagen, Gunhild
Basso, Trude
Gjertsen, Jan-Erik
Apalset, Ellen M.
Figved, Wender
Stutzer, Jens M.
Nissen, Frida I.
Hansen, Ann K.
Joakimsen, Ragnar M.
Figari, Elisa
Peel, Geoffrey
Rashid, Ali A.
Khoshkhabari, Jashar
Eriksen, Erik F.
Nordsletten, Lars
Frihagen, Frede
Dahl, Cecilie
Funding for this research was provided by:
University of Oslo
Article History
Received: 27 June 2023
Accepted: 15 August 2023
First Online: 24 August 2023
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was evaluated by the Norwegian Centre for Research Data (project number 587591). After performing a data protection impact assessment (DPIA), the project was approved by the data protection officer at the University of Oslo as pursuant to the General Data Protective Regulation EU 2016/679. Exemption from consent for quality assurance was obtained from the Norwegian Directorate of Health (ref:19/3103-4). The project was also approved by the data protection officer at all hospitals. All data was uploaded directly from the patient administrative systems (PAS) and from the x-ray/CT reports into the research platform “Services for Sensitive Data” (TSD), which meets the requirements of Norwegian law regarding safe handling and storing of sensitive data. All data merging, handling, and analyses were performed within this safe system.
: FF reports speaking fees from UCB and Amgen; TTB reports speaker fees from UCB, Amgen, Roche, and Pharma Prim. Advisory board for UCB; JEG reports lecture fees from Ortomedic Norway and LINK Norway; EMA reports advisory board for UCB and Amgen; RMJ reports consulting fees from Norwegian Directorate of Health, Norwegian Diabetes Association, Northern Norway Regional Health Authority and lecture fees from Novo Nordisk, Eli-Lilly, Astra-Zeneca, Sanofi; EFE reports consultant fees from UCB, Amgen, Gilead, Pharma Medico and honoraria from Amgen, UCB, and Novo Nordisk. The other authors declared that they have no conflict of interest.